Print version | PDF version | Send article | RSS feed

BD Biosciences Announces Agreement with Dynomics to Collaborate on Novel Cancer Diagnostic Technology

31 Mar 2006 - BD Biosciences, a segment of BD, announced a licensing and research agreement with Dynomics BV in the fields of leukemia and lymphoma. Under terms of the agreement, BD has an exclusive worldwide license to specific intellectual property related to the flow cytometry detection of fusion proteins. Financial terms were not disclosed.
 
Fusion proteins are unique proteins generated by a rearrangement of the chromosomes in a cell. Some disease states such as leukemia are characterized and sub-grouped by chromosomal rearrangements that generate well-recognized changes in cellular composition. Detection and identification of these proteins are important markers for diagnosing and monitoring leukemias. Dynomics focuses on the diagnosis and classification of leukemias and malignant lymphomas.